EP2192132A3 - Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen - Google Patents

Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen Download PDF

Info

Publication number
EP2192132A3
EP2192132A3 EP10152572A EP10152572A EP2192132A3 EP 2192132 A3 EP2192132 A3 EP 2192132A3 EP 10152572 A EP10152572 A EP 10152572A EP 10152572 A EP10152572 A EP 10152572A EP 2192132 A3 EP2192132 A3 EP 2192132A3
Authority
EP
European Patent Office
Prior art keywords
inflammation
antibodies
methods
binding partners
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10152572A
Other languages
English (en)
French (fr)
Other versions
EP2192132A2 (de
Inventor
Wenfeng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of EP2192132A2 publication Critical patent/EP2192132A2/de
Publication of EP2192132A3 publication Critical patent/EP2192132A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP10152572A 2005-02-08 2006-02-08 Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen Withdrawn EP2192132A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65083005P 2005-02-08 2005-02-08
EP06734517A EP1856156A2 (de) 2005-02-08 2006-02-08 Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP06734517.3 Division 2006-02-08

Publications (2)

Publication Number Publication Date
EP2192132A2 EP2192132A2 (de) 2010-06-02
EP2192132A3 true EP2192132A3 (de) 2010-08-18

Family

ID=36752302

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06734517A Withdrawn EP1856156A2 (de) 2005-02-08 2006-02-08 Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen
EP10152572A Withdrawn EP2192132A3 (de) 2005-02-08 2006-02-08 Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06734517A Withdrawn EP1856156A2 (de) 2005-02-08 2006-02-08 Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen

Country Status (7)

Country Link
US (2) US20060177447A1 (de)
EP (2) EP1856156A2 (de)
JP (1) JP2008532931A (de)
AU (1) AU2006212807A1 (de)
CA (1) CA2596390A1 (de)
IL (1) IL184567A0 (de)
WO (1) WO2006086396A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7801238B2 (en) * 2007-03-30 2010-09-21 Alcatel-Lucent Usa Inc. MIMO communication system with user scheduling based on reduced channel state information
US7611705B2 (en) * 2007-06-15 2009-11-03 National Cheng Kung University Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases
WO2010000721A1 (en) * 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
TW201014602A (en) * 2008-07-08 2010-04-16 Abbott Lab Prostaglandin E2 binding proteins and uses thereof
US8012478B2 (en) 2008-10-07 2011-09-06 National Cheng Kung University Use of anti-IL-20 antibody for treating stroke
US7837994B2 (en) * 2008-10-07 2010-11-23 National Cheng Kung University Use of anti-IL-20 antibody for treating osteoporosis
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
GB201508841D0 (en) * 2015-05-22 2015-07-01 Isis Innovation Treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2004085476A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578192A (en) * 1897-03-02 Henry h
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
EP0229046B1 (de) 1985-03-30 1994-05-04 BALLIVET, Marc Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5208146A (en) 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5783384A (en) 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0742830B1 (de) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
JP2000500015A (ja) 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド メチロトロープ性酵母におけるｇａｄ６５の生成
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
AU718510B2 (en) 1996-07-17 2000-04-13 Zymogenetics Inc. Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO1999007740A2 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
UA73275C2 (en) 1997-11-26 2005-07-15 Zymogenetics Inc A mammalian cytokine-like polypeptide
BR9914777A (pt) 1998-10-26 2001-07-03 Ludwig Inst Cancer Res Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
AU2253301A (en) * 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor
RU2279441C2 (ru) 1999-12-23 2006-07-10 Займодженетикс, Инк. Выделенный растворимый il-20 рецептор (варианты)
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU2001290837A1 (en) * 2000-09-15 2002-03-26 Zymogenetics Inc. Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
US20030022827A1 (en) * 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
JP2005510451A (ja) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
WO2002070655A2 (en) * 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
EP1399472B1 (de) 2001-03-09 2009-06-03 ZymoGenetics, Inc. Löslicher heterodimerer cytokinrezeptor
DE602004023965D1 (de) * 2003-11-21 2009-12-17 Zymogenetics Inc Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012345A2 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2004085476A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARRISH-NOVAK J ET AL: "INTERLEUKINS 19, 20, AND 24 SIGNAL THROUGH TWO DISTINCT RECEPTOR COMPLEXES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M205114200, vol. 277, no. 49, 6 December 2002 (2002-12-06), pages 47517 - 47523, XP008047447, ISSN: 0021-9258 *
XU WENFENG ET AL: "A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9511 - 9516, XP002186667, ISSN: 0027-8424 *
XU WENFENG: "Interleukin-20", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 4, no. 5, May 2004 (2004-05-01), pages 627 - 633, XP002589899, ISSN: 1567-5769 *

Also Published As

Publication number Publication date
EP1856156A2 (de) 2007-11-21
IL184567A0 (en) 2008-12-29
CA2596390A1 (en) 2006-08-17
JP2008532931A (ja) 2008-08-21
EP2192132A2 (de) 2010-06-02
US20060177447A1 (en) 2006-08-10
US20100111960A1 (en) 2010-05-06
WO2006086396A3 (en) 2006-09-28
WO2006086396A2 (en) 2006-08-17
AU2006212807A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
EP2192132A3 (de) Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
EP2103628A4 (de) Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
EP2311881A3 (de) Cripto-bindende Moleküle
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
EP1912674B8 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
EP2476706A3 (de) Anti-MN-Antikörper und Verfahren zu deren Verwendung
IL208859A0 (en) Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
WO2005103081A3 (en) Human monoclonal antibodies against cd20
EP1868647A4 (de) Ov064-bindende antikörper und verfahren zu ihrer verwendung
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
IL185491A0 (en) Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2006115800A3 (en) Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
SG156668A1 (en) Angiopoietin-2 specific binding agents
EP2631248A3 (de) Behandlung von Tumoren unter Verwendung eines spezifischen Anti-L1-Antikörpers
WO2008150530A3 (en) Cripto binding molecules
EP1742654A4 (de) Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
IL182186A0 (en) Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100203

AC Divisional application: reference to earlier application

Ref document number: 1856156

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110219